High-Risk Metachronous Oligometastatic Prostate Cancer Trial

Conditions: Prostate Cancer; Oligometastatic Disease Interventions: Drug: niraparib/abiraterone acetate; Radiation: Stereotactic ablative radiation therapy (SABR); Drug: Androgen deprivation therapy (ADT) Sponsors: University of Maryland, Baltimore; Janssen Scientific Affairs, LLC Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials